Table 3.
Studies reporting the development of new-onset PsA in patients with moderate-to-severe psoriasis treated with biologic therapy. * PASI at the diagnosis of PsA. ** Period of study enrolment.
| Reference | Type of Study | Treatment | New-Onset PsA | Male | Age (Years) |
PASI * | Period ** |
|---|---|---|---|---|---|---|---|
| Napolitano et al. [22] | Retrospective | Anti-TNFα, Anti-IL12/23 | 22/327 (6.7%) | 15/22 (68.2%) | 51.4 ±9.1 | 18.7 ± 12.1 | 2011–2015 |
| Van Muijen et al. [23] | Prospective | Anti-TNFα, Anti-IL12/23, Anti-IL17 | 32/342 (9.4%) | 15/32 (46.9%) | 57.2 ± 14.1 | 6.6 ± 6.6 | 2005–2018 |
| Asahina et al. [24] | Retrospective | Anti IL12/23 | 8/179 (4.5%) | 6/8 (75%) | 64.1 ± 18.8 | 12.0 ± 5.1 | 2011–2015 |
| Takahashi et al. [35] | Case report | Anti-IL12/23 | 1 | 1 (100%) | 79 | 1.9 | ----------------- |
| De Souza et al. [36] | Case series | Anti-IL12/23 | 2 | 2 (100%) | 39.5 ± 2.1 | 3.9 ± 1.8 | ----------------- |
| Jones et al. [37] | Case series | Anti-IL12/23 | 5 | 0 (0%) | 59 ± 8 | ----------------- | ----------------- |
| Stamell et al. [38] | Case series | Anti-IL12/23 | 2 | 2 (100%) | 45 ± 7.1 | ----------------- | ----------------- |
| Carija et al. [39] | Case report | Anti-IL 12/23 | 1 | 1 (100%) | 46 | ----------------- | ----------------- |
| Di Costanzo et al. [40] | Case series | Anti-TNFα | 1 | 1 (100%) | 46 | ----------------- | ----------------- |
| Vidal et al. [41] | Case report | Anti IL17 | 1 | 1 (100%) | 46 | 10 | ----------------- |
| Gisondi et al. [50] | Retrospective | Anti-TNFα, Anti-12/23, Anti-IL17 | 19/234 (8.1%) | ----------------- | ----------------- | ----------------- | 2012–2020 |
| Acosta Felquer et al. [51] | Retrospective | Anti-TNFα, Anti-IL12/23, Anti-IL17 | 2/103 (1.9%) | 67/103 (65.0%) | ----------------- | ----------------- | 2000–2018 |
----------------- stands for “not reported”.